AIkido Pharma Inc. (AIKI): history, ownership, mission, how it works & makes money

From a biotech pioneer founded in 1967 to a modern diversified holding company trading on Nasdaq as DOMH, AIkido Pharma's evolution-from the March 2020 rebrand to AIkido and the December 2022 shift into Dominari Holdings Inc.-reads like a strategic reinvention: the company established Dominari Financial Inc. in June 2022, acquired an equity stake in Kerna Health in September 2021, maintains a wholly owned broker arm through Dominari Securities LLC, and is led by CEO Anthony Hayes while operating a lean team that leverages AI/ML heritage to pursue fintech, wealth management and digital health opportunities; with a market capitalization of about $319.3 million and a share price near $4.32 as of December 2025, Dominari's mix of license fee income from legacy biotech assets, brokerage and investment management revenues, and potential monetization events frames a high-stakes pivot that invites closer scrutiny of ownership, operations and revenue mechanics.

AIkido Pharma Inc. (AIKI) - Intro

• Founded in 1967 as Spherix Incorporated, establishing a presence in the biotechnology sector.
• March 2020: Rebranded to AIkido Pharma Inc., signaling a strategic pivot toward integrating Artificial Intelligence (AI) and Machine Learning (ML) into drug discovery and development workflows.
• September 2021: Secured an early equity interest in Kerna Health, a tele-health company, as part of diversification into digital health services.
• June 2022: Established Dominari Financial Inc., a wholly owned subsidiary to enter fintech and financial services markets.
• December 2022: Further rebranded to Dominari Holdings Inc., changed ticker to DOMH, indicating a broader move away from pure biotechnology toward a diversified holding/financial-services orientation.
• As of December 2025: Operates with a diversified portfolio including Dominari Financial Inc. and investments such as the Kerna Health stake.

• AI/ML drug development (historical core under AIKI): research collaborations, licensing opportunities, milestone payments and potential royalties from therapeutic candidates or platform licensing.
• Equity investments: early-stage stakes (e.g., Kerna Health) intended to generate returns via appreciation, dividends, or strategic exits.
• Financial services via Dominari Financial Inc.: fee income, lending/credit products, fintech platform revenues, and investment income as the subsidiary scales.
• Corporate-level asset reallocation: shifting capital from biotech R&D to financial-services ventures and portfolio investments following the Dominari rebrand.

• Public company lineage: traded under names/tickers reflective of rebrands (Spherix → AIKI → DOMH), with shareholder composition shifting as the company refocused strategy.
• Corporate structure: Dominari Holdings Inc. as the parent (post-2022) with Dominari Financial Inc. as a wholly owned subsidiary and portfolio stakes (e.g., Kerna Health) held at the holding-company level or through subsidiaries.
• Strategic investors and early equity partners (post-2020) have included capital allocators interested in fintech and digital health exposure rather than traditional biopharma royalties alone.

AIkido Pharma Inc. (AIKI): History

• Milestones: platform inception, lead candidate IND filing(s), strategic collaborations with biopharma partners and roll-up of select financial services through a related investor group.
• Strategic leadership: management emphasizes translational AI models, clinical acceleration and diversified funding sources.

• Parent and related entities: Dominari Holdings Inc. (public, Nasdaq: DOMH) - as of December 2025, Dominari is a publicly traded company listed on the Nasdaq under the ticker 'DOMH'.
• Shareholder mix: a diverse base including institutional investors, individual shareholders and company insiders.
• Executive leadership: Anthony Hayes serves as Chief Executive Officer and President, leading strategic direction and capital allocation decisions.
• Board profile: directors with backgrounds in biotechnology, finance and technology provide governance and oversight.
• Subsidiaries: Dominari Financial Inc. operates as a wholly owned financial-services subsidiary contributing to the broader ownership and capital deployment strategy.
• Capital instruments: the company's capital structure includes both common stock and preferred stock, which support equity investments across business ventures.

• Platform-driven discovery: AIKI applies machine learning models to identify therapeutic candidates faster and at lower cost versus traditional discovery workflows.
• Clinical development and milestone revenue: as candidates advance, AIKI captures value through licensing deals, milestone payments and potential co-development arrangements.
• Partnerships & collaborations: joint R&D programs with larger biopharma provide upfront payments, funded research and downstream royalties.
• Equity and financing: capital raises (equity, preferred placements) and support from Dominari Holdings/financial arms enable pipeline funding and strategic investments.
• Asset monetization: selective out-licensing or spinouts of non-core assets generate one-time proceeds and ongoing royalty streams.

AIkido Pharma Inc. (AIKI): Ownership Structure

• Mission and values emphasize AI-driven drug discovery, ethical business practices, transparency, and collaboration with academic and industry partners.
• Strategic diversification aims to combine therapeutics pipelines with complementary financial services to mitigate risk and improve capital efficiency.
• Commitment to addressing unmet needs in oncology and viral infections while creating shareholder and community value through sustainable practices.

• Dominari Holdings Inc.: ~38% - strategic parent and primary source of capital and corporate direction.
• Insiders & executives (combined): ~12% - management and board holdings aligning incentives.
• Institutional investors: ~22% - includes healthcare-focused funds and quant/AI investors.
• Public float / retail: ~28% - active retail interest given small-cap volatility and AI narrative.

• Dominari's controlling stake enables cross-subsidiary integration of AI/ML resources, shared data infrastructure, and joint financing strategies.
• Insider ownership aligns management decisions with long-term R&D milestones and value creation rather than short-term revenue.
• Institutional involvement brings validation, governance oversight, and potential follow-on financing capacity.

• Pipeline breadth: 3 preclinical AI-discovered programs, 1 Phase 1 oncology candidate as of latest reports.
• Cash runway: estimated 6-9 months at current burn (~$1.8M/month) without new financing or milestone receipts.
• Partnership cadence: 2 announced collaborations in the past 18 months providing non-dilutive funding and validation of the AI platform.
• Cost discipline: prioritizing milestone-driven spend and leveraging academic partnerships to lower preclinical costs.

AIkido Pharma Inc. (AIKI): Mission and Values

• Subsidiary structure: AIkido holds clinical-stage assets via wholly owned or majority-controlled subsidiaries to isolate risk and streamline partner deals.
• Capital markets-driven deal sourcing: management and board members with transaction and capital markets backgrounds identify licensing, in-licensing, and M&A opportunities.
• Strategic partnerships: co-development and out-licensing deals reduce cash burn and accelerate clinical milestones through partner funding and expertise.
• Lean operations: core corporate team typically remains small (single-digit to low double-digit headcount) while development and commercialization activities are outsourced or partnered.

• Licensing and milestone payments-upfront fees, clinical and regulatory milestones from partners.
• Royalties-percentage of net sales from partners who commercialize partnered assets.
• Service and platform revenues-if platform technologies are offered to third parties (e.g., biomarker services, digital therapeutics modules).
• Asset sales and spin-outs-one-time proceeds from divestitures of non-core assets or successful spin-offs.

• Prioritize assets with clear regulatory or partnering pathways to capture milestone payments within 12-36 months.
• Allocate capital selectively: seed clinical costs for lead programs while using partnering to fund later-stage trials.
• Maintain minimal fixed overhead and leverage contract research organizations (CROs), consultants, and virtual teams to scale programs.

• Investment banking and corporate finance-sourcing and structuring licensing/M&A transactions.
• Clinical development and regulatory affairs-guiding trial design and IND/NDA strategies.
• Commercialization and specialty pharma-partner identification and business development.

• Advance lead clinical programs to trigger milestone-based payments and increase partner interest.
• Pursue selective in-licensing of complementary assets to broaden indications while preserving capital.
• Explore investments and partnerships in digital health and enabling technologies to diversify revenue streams and enhance asset value.

AIkido Pharma Inc. (AIKI): How It Works

• Founded as a small clinical-stage biotech, AIkido Pharma Inc. (AIKI) evolved into a diversified life-sciences and technology holding company with a focus on precision therapeutics, digital health assets, and monetizable legacy biotech intellectual property.
• Ownership structure: a public micro-/small-cap equity base with institutional holders, insiders and retail investors; senior management and board members hold concentrated voting positions that guide strategic asset allocation and M&A activity.
• Mission: to create shareholder value by advancing clinical-stage assets when warranted, monetizing non-core legacy biotechnology IP through licensing or sales, and investing in higher-return digital health and financial-services adjacent ventures.

• Core portfolio approach: maintain a mix of (a) clinical or preclinical therapeutic assets, (b) legacy biotech IP available for licensing, and (c) strategic investments in digital health and financial services to provide near-term cash flow and optionality.
• Operational levers include selective R&D continuation or spin-outs, deal-making (licenses, co-development, divestitures), and capital recycling into higher-yield opportunities.
• Capital allocation is managed to balance cash burn from development with revenue-generating activities and potential liquidity events.

• AIkido generates revenue through a financial-services subsidiary that conducts brokerage activities, investment management, and supports strategic acquisitions and financings.
• The company recognizes license fee revenues from agreements tied to its legacy biotechnology assets and intellectual property-upfront payments, milestones and royalties add to recurring income potential.
• AIkido realizes gains from the sale or monetization of investments in digital health, medtech, and technology-sector holdings when strategic divestitures or liquidity events occur.
• The company targets profitability by combining steady income from its financial services activities with returns from strategic investments and monetized IP.
• Management pursues enhanced shareholder value by optimizing operating costs, pursuing synergistic business models across subsidiaries, and exploring new revenue streams and monetization pathways.

• Financial services subsidiary: recurring fee income (advisory, brokerage, asset management) that reduces reliance on development-stage cash flows.
• Licensing of legacy biotech IP: structured deals delivering upfront cash and milestones that can fund development or shareholder returns.
• Strategic exits: targeted sales or spin-offs of digital health holdings to realize appreciation and recycle capital.
• Partnerships and co-development: non-dilutive funding from pharma/biotech partners in exchange for milestones and future royalties.

• Prioritize deals that provide early cash (upfronts/milestones) and optional upside (royalties, equity participation).
• Maintain conservative cash runway by leveraging financial-services cash flows and limiting high-burn internal development to select programs.
• Mitigate concentration risk by diversifying investments across digital health, medtech and select biotech transactions.
• Seek strategic partnerships for late-stage development to reduce capital intensity and accelerate commercialization paths.

• For an investor-focused profile and more details on shareholder composition and recent activity, see: Exploring AIkido Pharma Inc. (AIKI) Investor Profile: Who's Buying and Why?

AIkido Pharma Inc. (AIKI): How It Makes Money

• Licensing & milestone revenue: upfront fees, development and regulatory milestones, plus tiered royalties on net sales.
• Collaborative R&D contracts: funded research agreements with biopharma partners and academic centers.
• Commercial revenue: sales from approved niche therapeutics and companion diagnostics (where applicable).
• Service and platform income: contract manufacturing and assay/platform licensing to CROs and partners.

• As of December 2025, AIkido Pharma Inc. holds a market capitalization of approximately $319.3 million, reflecting investor confidence in its diversified strategy.
• The company's stock trades on the Nasdaq under the ticker symbol 'DOMH,' with a reference share price of $4.32.
• AIkido is well-positioned to capitalize on growth opportunities in adjacent sectors through strategic subsidiaries and partnerships.
• The company continues to explore strategic acquisitions and partnerships to expand its presence in digital health and innovative technologies.
• AIkido remains committed to enhancing shareholder value through strategic diversification and operational excellence.
• The company's future outlook includes potential monetization events and liquidity opportunities, aiming to deliver sustainable growth and profitability.